What Is the Glow Blend?
The Glow Blend is a tri-peptide research compound that combines three complementary regenerative peptides in a single vial: GHK-Cu (50mg), a copper-binding tripeptide with a long history of dermatological and wound-healing research; BPC-157 (10mg), a synthetic pentadecapeptide derived from human gastric juice that has been studied for tissue and vascular repair; and TB-500 (10mg), a synthetic analog of the active region of Thymosin β4 that has been investigated for actin sequestration, angiogenesis, and broad tissue regeneration.
By combining these three peptides into a single research blend, Glow is designed to target multiple regenerative pathways simultaneously, copper-mediated collagen remodeling via GHK-Cu, cytoprotective and vascular signaling via BPC-157, and actin/angiogenesis-driven tissue repair via TB-500. This approach mirrors the stacked peptide protocols most commonly referenced in applied dermatological and recovery research.
Peptide Profile
Product: Glow Blend (tri-peptide research compound)
Components: GHK-Cu 50mg · BPC-157 10mg · TB-500 10mg
GHK-Cu: Copper-binding tripeptide (Gly-His-Lys), ~340 Da
BPC-157: 15-residue peptide (Body Protection Compound), ~1,419 Da
TB-500: 17-residue fragment of Thymosin β4, ~1,936 Da
Classification: Aesthetic + regenerative research blend
Mechanism of Action
The Glow Blend targets multiple, complementary regenerative pathways. Each peptide operates through a distinct but overlapping mechanism, and the combination has been of research interest for its potential to address skin quality, soft-tissue repair, and systemic recovery in parallel.
GHK-Cu: Copper Transport & Dermal Remodeling
GHK-Cu is a tripeptide (Gly-His-Lys) with a high affinity for copper(II) ions. Research has shown it facilitates copper transport into cells, modulates expression of over 4,000 genes in dermal fibroblasts, and promotes collagen, elastin, and glycosaminoglycan synthesis. Published studies highlight its role in wound healing, hair follicle stimulation, antioxidant defense, and skin remodeling, earning it a well-established position in dermatological peptide research.
BPC-157: Cytoprotection & Vascular Signaling
BPC-157 is a 15-amino-acid sequence derived from a protective protein isolated from human gastric juice. Preclinical research has demonstrated angiogenic effects through upregulation of VEGFR-2, modulation of the nitric oxide system, and accelerated repair of soft tissues including tendon, ligament, muscle, and GI mucosa. BPC-157 has become one of the most studied peptides in tissue-repair literature, and its inclusion in the Glow blend targets the connective-tissue side of regeneration.
TB-500: Actin Sequestration & Angiogenesis
TB-500 is a synthetic analog of the active region of Thymosin β4, a naturally occurring protein involved in cell migration, differentiation, and wound repair. Its primary mechanism is actin sequestration, which regulates cell motility and enables tissue regeneration. Research has also shown TB-500 promotes new blood-vessel formation (angiogenesis), reduces inflammation, and accelerates recovery in models of soft-tissue injury, skin wounds, and cardiac stress.
Synergistic Stacking Rationale
Each peptide in the Glow blend operates through a different but complementary pathway. GHK-Cu drives dermal gene expression and copper-mediated collagen synthesis, BPC-157 modulates vascular and cytoprotective signaling, and TB-500 drives actin-based tissue regeneration and angiogenesis. Stacked research protocols investigate whether combining these signals produces broader regenerative coverage than any single peptide alone, making this blend a natural fit for applied aesthetic and recovery research.
Research Overview
Each component of the Glow blend has its own extensive research base. The following table summarizes key research areas for the combined components of the blend.
| Research Area | Key Findings | Study Type |
|---|---|---|
| Skin & Collagen (GHK-Cu) | Studies demonstrate stimulation of collagen, elastin, and glycosaminoglycan synthesis, plus improved dermal density and firmness in human trials | In vitro & in vivo (human) |
| Wound Healing (GHK-Cu) | Published research documents accelerated wound closure, antioxidant activity, and reduced inflammation in dermal injury models | In vivo (animal/human) |
| Tissue Repair (BPC-157) | Preclinical studies demonstrate accelerated healing of tendon, ligament, muscle, and GI tissue in rodent injury models | In vivo (rodent) |
| Angiogenesis (BPC-157) | Research demonstrates upregulation of VEGFR-2 and formation of new blood vessels in healing tissue | In vitro & in vivo |
| Actin & Cell Migration (TB-500) | Research documents actin sequestration, enhanced cell migration, and improved regeneration in soft-tissue models | In vitro & in vivo |
| Recovery & Angiogenesis (TB-500) | Preclinical research shows accelerated injury recovery, anti-inflammatory effects, and pro-angiogenic activity | In vivo (animal) |
The components of the Glow blend collectively have one of the deepest research footprints of any peptide stack. GHK-Cu has decades of published dermatological and wound-healing research, BPC-157 has an extensive preclinical record across tissue types, and TB-500 has been widely studied in cardiac, musculoskeletal, and wound healing models. Stacked research interest reflects the overlap and complementarity of these mechanisms.
Common Areas of Research Interest
Scientific interest in the Glow blend centers on the combined regenerative footprint of its three components, particularly for applied research into skin quality, tissue healing, and recovery.
- Skin quality & collagen, GHK-Cu is extensively studied for collagen synthesis, dermal remodeling, and visible skin firmness in dermatological research
- Wound healing, Published research documents accelerated wound closure and antioxidant effects of GHK-Cu in dermal injury models
- Tissue & connective repair, BPC-157 has been studied in tendon, ligament, muscle, and GI tract injury models with accelerated recovery endpoints
- Angiogenesis & vascular support, Both BPC-157 and TB-500 have demonstrated pro-angiogenic activity in preclinical research
- Systemic recovery, TB-500 is investigated for broad soft-tissue and cardiac recovery through actin sequestration and cell migration
- Aesthetic & anti-aging research, The combined mechanisms of the blend are of interest in research into skin aging, barrier function, and visible tissue quality
Pharmacokinetics
The pharmacokinetic profile of the Glow blend reflects the properties of its three component peptides. The following parameters summarize key pharmacokinetic characteristics reported in the literature for each component.
Each component of the Glow blend has a distinct pharmacokinetic profile. GHK-Cu has a short plasma half-life but exerts prolonged dermal effects through copper transport and gene expression modulation. BPC-157 shows remarkable stability in gastric juice and plasma with a reported half-life of approximately 4 hours. TB-500 has the longest circulatory persistence of the three due to its larger size and structural stability. In research literature, the blend is most commonly investigated via subcutaneous administration after reconstitution with bacteriostatic water.
Comparison to Similar Peptides
The Glow blend sits within a broader landscape of regenerative and aesthetic research peptides. The following comparison highlights key distinctions between the blend and its individual components.
| Feature | Glow Blend | GHK-Cu (solo) | BPC-157 (solo) | TB-500 (solo) |
|---|---|---|---|---|
| Classification | Tri-peptide blend | Copper tripeptide | Synthetic pentadecapeptide | Thymosin β4 fragment |
| Amino Acids | 3 + 15 + 17 | 3 (Gly-His-Lys) | 15 | 17 |
| Plasma Half-Life | Varies by component | Short | ~4 hrs | Longer (larger MW) |
| Primary Target | Skin + tissue + recovery | Copper transport, collagen | Angiogenesis, cytoprotection | Actin, cell migration |
| Primary Research Focus | Aesthetic + systemic recovery | Dermal / hair research | Tissue & connective repair | Soft-tissue & cardiac recovery |
| Typical Route | Subcutaneous | SC or topical | Subcutaneous | Subcutaneous |
Glow vs KLOW, Side-by-Side
KLOW is Somata's premium upgrade to the Glow research blend. It retains the full tri-peptide base of Glow, GHK-Cu (50mg), BPC-157 (10mg), and TB-500 (10mg), and adds a fourth peptide: KPV (10mg), a C-terminal tripeptide of α-MSH (Lys-Pro-Val) studied for its anti-inflammatory, mast-cell-stabilizing, and antimicrobial properties. The result is an 80mg four-peptide research compound designed to layer inflammation modulation on top of Glow's existing regenerative footprint.
KPV (Lys-Pro-Val) is the three-residue C-terminal fragment of alpha-melanocyte-stimulating hormone (α-MSH). Preclinical research has investigated KPV for potent anti-inflammatory signaling (via NF-κB pathway modulation), mast cell stabilization, gut mucosal protection in IBD/colitis models, antimicrobial activity, and support of wound healing. In a stacked research compound, KPV complements GHK-Cu's collagen and dermal remodeling work, BPC-157's cytoprotective signaling, and TB-500's actin-driven tissue regeneration, giving KLOW a broader inflammation and barrier-support footprint than Glow alone.
| Feature | Glow Blend | KLOW Blend |
|---|---|---|
| Classification | Tri-peptide research blend | Quad-peptide premium research blend |
| Components | GHK-Cu 50mg · BPC-157 10mg · TB-500 10mg | GHK-Cu 50mg · BPC-157 10mg · TB-500 10mg · KPV 10mg |
| Total Peptide Content | 70 mg | 80 mg |
| Peptide Count | 3 | 4 |
| Anti-inflammatory Coverage | Indirect, via BPC-157 & TB-500 | Direct, via KPV NF-κB modulation + BPC-157 / TB-500 |
| Mast Cell Stabilization | Not a primary mechanism | KPV-driven mast cell stabilization included |
| Skin & Collagen Research | GHK-Cu primary driver | GHK-Cu + KPV complementary dermal signaling |
| Gut / Barrier Research | BPC-157 GI cytoprotection | BPC-157 cytoprotection + KPV mucosal & barrier support |
| Tissue Repair & Angiogenesis | BPC-157 + TB-500 | BPC-157 + TB-500 (unchanged) |
| Positioning | Core aesthetic & recovery stack | Premium upgrade: aesthetics + inflammation + barrier |
| Typical Research Route | Subcutaneous (GHK-Cu also topical) | Subcutaneous (KPV also studied orally & topically) |
| Price | $160 | $175 |
When researchers choose Glow: when the focus is on the core dermatological and regenerative signature of GHK-Cu, BPC-157, and TB-500 without the added inflammation-specific layer.
When researchers choose KLOW: when the research model emphasizes inflammation modulation, gut / barrier function, mast-cell activity, or maximum peptide coverage in a single vial, and the additional $15 over Glow is justified by KPV's inclusion.
Explore KLOW
Premium four-peptide research compound. Third-party tested for purity and identity.
View KLOWThis product is intended for research and laboratory use only. It is not intended for human consumption.
Frequently Asked Questions
Sources & References
- Pickart L, Margolina A. "Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data." International Journal of Molecular Sciences. 2018;19(7):1987. PubMed
- Pickart L, et al. "GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration." BioMed Research International. 2015;2015:648108. PubMed
- Sikiric P, et al. "Stable gastric pentadecapeptide BPC 157 and wound healing." Frontiers in Pharmacology. 2021;12:627533. PubMed
- Chang CH, et al. "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration." Journal of Applied Physiology. 2011;110(3):774-780. PubMed
- Huang T, et al. "Bodily injury caused by chronic ischemic colitis reversed by BPC 157." Journal of Physiology and Pharmacology. 2019. PubMed
- Goldstein AL, Hannappel E, Kleinman HK. "Thymosin β4: actin-sequestering protein moonlights to repair injured tissues." Trends in Molecular Medicine. 2005;11(9):421-429. PubMed
- Malinda KM, et al. "Thymosin β4 accelerates wound healing." Journal of Investigative Dermatology. 1999;113(3):364-368. PubMed
- Smart N, et al. "Thymosin β4 induces adult epicardial progenitor mobilization and neovascularization." Nature. 2007;445(7124):177-182. PubMed
Explore the Glow Blend
Available for research purposes. Third-party tested for purity and identity.
View Glow Blend — $160This product is intended for research and laboratory use only. It is not intended for human consumption.